Morbidity and Mortality Weekly Report最新文献

{"title":"Emergence of Extensively Drug-Resistant Shigellosis - United States, 2011-2023.","authors":"Naeemah Logan,Meseret G Birhane,Sharla L McDonald,Jemma Alarcón,Salette Amador,Madhu Anand,Laura H Bachmann,Kevin Bernard,Lindsay S Black,Angela N Chen,Laura A Cooley,Esther D Fortes,Marisa Gerard,Rachel H Jervis,Akiko C Kimura,Katherine Lamba,Julia Latash,Linlin Li,Grace Pederson,Carley Perez Kauffman,Jared L Reynolds,Richard Santiago,Ulrike Siemetzki-Kapoor,Sandra C Smole,Kaitlin A Tagg,Johanna Vostok,Hattie E Webb,Louise K Francois Watkins, ","doi":"10.15585/mmwr.mm7513a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7513a1","url":null,"abstract":"Shigellosis is a nationally notifiable diarrheal illness caused by gram-negative bacteria. Shigella infection is spread through fecal-oral transmission and sexual contact. Although most infections are self-limited, antibiotics are indicated for severe illness or to reduce transmission in settings with high risk for spread. Since 2015, a growing proportion of cases has been caused by extensively drug-resistant (XDR) Shigella species, defined as being resistant to ampicillin, azithromycin, ceftriaxone, ciprofloxacin, and trimethoprim-sulfamethoxazole. No Food and Drug Administration-approved oral antimicrobial agents are available to treat these XDR infections. To describe U.S. trends and epidemiologic characteristics of XDR shigellosis, CDC analyzed Shigella isolates submitted to PulseNet, CDC's molecular surveillance network for enteric pathogens, during January 1, 2011-October 20, 2023; antimicrobial resistance was characterized using whole-genome sequencing data and antimicrobial susceptibility testing. Among 16,788 isolates with resistance data during this period, 510 (3.0%) were XDR. The percentage of XDR isolates increased from 0% during 2011-2015 to 8.5% in 2023. Species information was available for 505 (99%) of 510 XDR isolates; among those, 333 (65.9%) were Shigella sonnei and 172 (34.1%) were Shigella flexneri. Among patients with XDR shigellosis, the median patient age was 41 years (IQR = 31-54 years) and 86.2% were men. Among patients with available travel history, 76.2% (173 of 227) reported no recent domestic travel and 82.4% (169 of 205) reported no recent international travel. Among 116 persons with available HIV status, 54 (46.6%) reported HIV co-infection. Strengthened surveillance, timely reporting, and targeted prevention strategies are needed to limit transmission of XDR Shigella strains.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"5 1","pages":"173-178"},"PeriodicalIF":0.0,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.","authors":"Jelonia T Rumph,Andrea Winquist,Alyssa N Troeschel,Skylar Pulver,Amy Helene Schnall,Joseph Ebersole,Michael Yeh,Brooke Burt,Sharon L Federman,Karl Klontz,Catherine Dasenbrock,Heather L Leahy,Shane Brady,Haylea Stuteville,Ketki Patel,Johnni Daniel,Arthur Chang","doi":"10.15585/mmwr.mm7513a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7513a2","url":null,"abstract":"In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In response to this alert, CDC and the Food and Drug Administration coordinated a nationwide outbreak investigation to characterize the potential poisonings associated with eating Diamond Shruumz microdosing chocolate bars. A case of poisoning was defined as an illness with moderate or major clinical effects (i.e., symptoms) as defined by America's Poison Centers in a person who ate any Diamond Shruumz product or another mushroom-containing chocolate product during January-October 2024. In total, 180 cases were reported in 34 states. Among these, 73 persons were hospitalized, including 38 persons who required intensive care unit (ICU) admission, 29 who required endotracheal intubation, and two deaths. Eating Diamond Shruumz chocolate bars was associated with higher odds of hospitalization (odds ratio [OR] = 3.29; 95% CI = 1.51-7.40), ICU admission (OR = 6.30; 95% CI = 2.17-22.6), seizures (OR = 8.45; 95% CI = 3.00-27.9), and endotracheal intubation (OR = 8.04; 95% CI = 2.24-44.2), compared with eating other mushroom-containing chocolate products. Eating larger amounts of Diamond Shruumz chocolate bars was associated with an increased likelihood of hospitalization, ICU admission, and endotracheal intubation (p-value for trend tests [p-trend] = 0.023, 0.004, and <0.001, respectively). Diamond Shruumz products were recalled, and the public was advised not to eat, sell, or serve any Diamond Shruumz products and to discard any Diamond Shruumz products previously purchased. Testing of some Diamond Shruumz products identified substances present in psychoactive mushrooms, including muscimol, psilocin (a Schedule I controlled substance), kavalactones, and other substances in some, but not all, tested products. Consumers should be aware of the poisoning risk associated with eating Diamond Shruumz products and other mushroom-containing microdosing chocolate products due to variability in ingredient composition, the absence of standardized regulatory oversight for sampling and testing finished products, and the potential toxicity of compounds intended to produce psychoactive effects.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"62 1","pages":"179-184"},"PeriodicalIF":0.0,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increase in Poison Center Reports Linked to Kratom-Containing Kava Products - National Poison Data System, United States, 2000-2025.","authors":"Eleanor Blair Towers,Ivy L Williams,Christopher P Holstege,Rita Farah","doi":"10.15585/mmwr.mm7512a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7512a1","url":null,"abstract":"Kava (Piper methysticum), a central nervous system depressant derived from a plant in the pepper family native to the Pacific Islands, is traditionally consumed in religious, cultural, political, and social ceremonies. In the United States, kava emerged in the late 1990s and has experienced renewed growth and product diversification since the 2010s, with increasing availability of concentrated extracts and ready-to-drink beverages. These commercial products are commonly marketed as healthy alternatives to alcohol, sold near college campuses, and increasingly being combined with kratom, a psychoactive botanical with opioid-like effects, raising safety concerns. Data on kava-related use during January 2000-December 2025 that resulted in a report to the National Poison Data System (i.e., kava exposure report) were analyzed to assess trends by users' demographic characteristics, exposure type, and outcomes. Kava-related exposure reports declined sharply after a 2002 Food and Drug Administration advisory on kava-associated severe liver injury but have risen steadily since 2011, reaching 203 reported exposures in 2025. Reports primarily involved adults aged ≥20 years, but demographic characteristics have changed over time. During 2000-2001, reports primarily involved females and included more children aged ≤12 years, whereas exposure reports since 2013 have predominantly involved men; reports involving children have been rare. Since 2017, reports involving combined use of kava and kratom have increased, reaching 30% (61) of all kava reports in 2025. These increases have coincided with higher rates of serious reported clinical outcomes in recent years (32% in 2025 compared with 12% in 2000). These data indicate a resurgence of overall kava exposure reports to poison centers, as well as an increase in kratom-related kava reports, which has coincided with higher rates of serious clinical outcomes. The findings in this report suggest the need for enhanced surveillance for, clinical awareness of, and public education regarding commercial products containing kava.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"4 1","pages":"157-163"},"PeriodicalIF":0.0,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147599503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season.","authors":"Mehreen Meghani,Zhuping Garacci,Hilda Razzaghi,Marie A de Perio,A Scott Laney,Jennifer L Kriss,Carla L Black","doi":"10.15585/mmwr.mm7512a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7512a2","url":null,"abstract":"The Advisory Committee on Immunization Practices (ACIP) recommends that all health care personnel (HCP) receive an annual influenza vaccination to reduce the risk for influenza and influenza-related morbidity and mortality among themselves and their patients. For the 2024-25 respiratory virus season, ACIP also recommended that all HCP be vaccinated against COVID-19. During March 26-April 17, 2025, CDC conducted a nonprobability opt-in internet panel survey of 2,650 U.S. HCP to estimate influenza and COVID-19 vaccination coverage during the 2024-25 respiratory virus season. Overall, 76.3% of HCP reported having received an influenza vaccine and 40.2% reported receiving the 2024-25 COVID-19 vaccine. Influenza vaccination coverage was highest among pharmacists (94.6%), physicians (92.6%), and HCP who worked in hospital settings (88.3%). COVID-19 vaccination coverage was highest among physicians (46.7%), assistants or aides (46.7%), and HCP who worked in long-term care and home health care settings (44.5%). Both influenza and COVID-19 vaccination coverage rates were highest among HCP whose employer required or recommended the vaccines or offered them on-site. A multipronged approach, including educating HCP about benefits of vaccination and implementing workplace strategies (such as employer vaccination recommendations or offering on-site vaccination) might improve vaccination coverage and reduce influenza- and COVID-19-related morbidity among HCP.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"120 1","pages":"164-171"},"PeriodicalIF":0.0,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147599494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increases in Kratom-Related Reports to Poison Centers - National Poison Data System, United States, 2015-2025.","authors":"Eleanor Blair Towers,Ynhi T Thomas,Christopher P Holstege,Rita Farah","doi":"10.15585/mmwr.mm7511a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7511a1","url":null,"abstract":"Kratom, the leaves of a tropical evergreen tree (Mitragyna speciosa), is traditionally consumed in Southeast Asia for pain relief, mood enhancement, and to relieve symptoms of opioid withdrawal. Kratom contains psychoactive compounds that interact with opioid receptors and is widely available in various forms in the United States. Its evolution from natural leaf to high-potency alkaloid products has raised concerns about toxicity. Data on kratom-related use that resulted in a report to the National Poison Data System (NPDS) (i.e., kratom exposure report) during 2015-2025 were analyzed to assess trends by exposure report type, demographic characteristics of persons exposed, and outcomes. During the past 11 years, poison centers received a total of 14,449 kratom exposure reports; the record high 3,434 reports in 2025 represent an increase of approximately 1,200% compared with the 258 reports in 2015. Most reports involved males and young adults aged 20-39 years, but reports among adults aged 40-59 years increased most sharply, with rates nearly overlapping with those among young adults by 2025. Although single-substance exposure reports accounted for most reports (62%), multiple-substance reports occurred at higher rates (range = 467-5,442 per 1 million multiple-substance drug exposure reports versus 388-4,045 per 1 million single-substance drug exposure reports), were associated with more hospitalizations (44%-56% versus 24%-29% annually) and serious (life threatening, pronounced, prolonged, or systemic) outcomes (57%-66% versus 41%-49% annually), and accounted for the vast majority of kratom-associated deaths during the study period (184 of 233; 79%). NPDS data indicate that kratom-related reports to poison centers are increasing and expanding among demographic groups, underscoring the value of ongoing surveillance to identify high-risk patterns of kratom use and guide strategies to reduce risks from multiple-substance exposure reports.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"18 1","pages":"139-145"},"PeriodicalIF":0.0,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 - Worldwide, November 2024-February 2026.","authors":"Mila Shakya,Kevin C Ma,Laura J Hughes,Casey Smith,Lydia J Atherton,Alexandria B Boehm,Peter W Cook,Daniel M Cornforth,Meredith Gardner,Iryna V Goraichuk,Jennifer L Harcourt,Heather Hicks,Marc Johnson,Anna Kelleher,Heather E Reese,Susanna J Sabin,Teresa C Smith,Azaibi Tamin,Marlene K Wolfe,Benjamin J Silk,Clinton R Paden,Natalie Thornburg,Adam MacNeil","doi":"10.15585/mmwr.mm7510a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7510a1","url":null,"abstract":"The SARS-CoV-2 variant BA.3.2 was first identified in South Africa on November 22, 2024. BA.3.2 has approximately 70-75 substitutions and deletions in the gene sequence of the spike protein relative to JN.1 and its descendant, LP.8.1, the antigens used in the 2025-26 COVID-19 vaccines. CDC is using a multimodal SARS-CoV-2 genomic surveillance approach to monitor the emergence and spread of BA.3.2 and other SARS-CoV-2 variants internationally and within the United States. The first U.S. BA.3.2 detection occurred on June 27, 2025, through CDC's Traveler-Based Genomic Surveillance program in a participant traveling to the United States from the Netherlands. The first U.S. detection of BA.3.2 in a clinical specimen collected from a patient was reported on January 5, 2026. As of February 11, 2026, BA.3.2 had been detected in voluntarily self-collected nasal swabs from four U.S. travelers, clinical samples from five patients, three airplane wastewater samples, and 132 wastewater surveillance samples from 25 states. BA.3.2 has been reported by at least 23 countries. SARS-CoV-2 continues to cause substantial morbidity and mortality worldwide. BA.3.2 mutations in the spike protein have the potential to reduce protection from a previous infection or vaccination. Continued genomic surveillance is needed to track SARS-CoV-2 evolution and determine its potential effect on public health.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"44 1","pages":"130-137"},"PeriodicalIF":0.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.","authors":"Patrick Maloney,Emily L Reeves,Kristina Wielgosz,Ashley M Price,Karthik Natarajan,Malini B DeSilva,Kristin Dascomb,Nicola P Klein,Sara Y Tartof,Stephanie A Irving,Shaun J Grannis,Toan C Ong,Zachary A Weber,Jennifer E Schuster,Danielle M Zerr,Marian G Michaels,Julie A Boom,Natasha B Halasa,Mary A Staat,Geoffrey A Weinberg,Stacey L House,Elie A Saade,Krissy Moehling Geffel,Manjusha Gaglani,Karen J Wernli,Vel Murugan,Emily T Martin,Natalie A B Bontrager,Marie K Kirby,Amanda B Payne,Fatimah S Dawood,Ayzsa Tannis,Heidi L Moline,Sifang Kathy Zhao,Katherine Adams,Jennifer DeCuir,Samantha M Olson,Jessie R Chung,Nathaniel Lewis,Brendan Flannery,Carrie Reed,Shikha Garg,Sascha Ellington, , ","doi":"10.15585/mmwr.mm7509a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7509a2","url":null,"abstract":"In the United States, annual influenza vaccination has been recommended for all persons aged ≥6 months, including during the 2025-26 season. Interim influenza vaccine effectiveness (VE) estimates were calculated for patients with acute respiratory illness-associated outpatient visits and hospitalizations from three U.S. respiratory virus VE networks during the 2025-26 influenza season, using a test-negative case-control design. Among children and adolescents aged <18 years, VE was 38%-41% against influenza outpatient visits and 41% against influenza-associated hospitalization. Among adults aged ≥18 years, VE was 22%-34% against influenza outpatient visits and 30% against influenza-associated hospitalization. Among children and adolescents, VE against influenza A ranged from 37% (against outpatient visits) to 42% (against hospitalization) across settings; among adults, VE against influenza A ranged from 30% (against hospitalization) to 34% (against outpatient visits) across settings. Among children and adolescents, VE against influenza A(H3N2)-associated outpatient visits was 35% and against influenza A(H3N2)-associated hospitalization was 38%. VE against influenza B outpatient visits ranged from 45%-71% among children and adolescents and was 63% among adults. Other estimates of VE were not statistically significant or were not reportable. Although interim influenza VE is lower during the 2025-26 influenza season than it was during recent influenza seasons, these findings demonstrate that influenza vaccination still provides protection against influenza. CDC recommends influenza vaccination; U.S. influenza vaccines remain available for persons aged ≥6 months.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"8 1 1","pages":"116-123"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measles Outbreak - New Mexico, 2025.","authors":"Emma Stanislawski,Andrea Romero,Nora Holzinger,Ruth Healy,Nathaniel J Webb,Kathryn Cruz,Marla Sievers,Su Aung,Samantha Swisher,Ruth Stefanos,Jennifer Yara-Zelenski,Aaron D Kofman,Rebecca Pierce,Chisom Onyeuku,Kara McGinnis Pilote,Jessica Leung,Chad Smelser","doi":"10.15585/mmwr.mm7509a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7509a1","url":null,"abstract":"Measles is a highly contagious respiratory virus with the potential to cause large outbreaks, as well as serious complications, hospitalization, and death. Receipt of 2 doses of measles vaccine is 97% effective at preventing disease and is recommended for all persons aged ≥12 months to ensure high levels of population immunity and reduce the risk for outbreaks. In January 2025, a large measles outbreak began in a west Texas community and quickly spread to nearby jurisdictions, including New Mexico. The New Mexico Department of Health (NMDOH) eventually reported 99 outbreak-related measles cases, approximately one half of which occurred in adults. To facilitate dissemination of information and distribution of resources across a geographically large, rural state, NMDOH implemented a multimodal communication and vaccination outreach strategy, including a centralized webpage, a telephone helpline, and mobile vaccination clinics. The outreach strategy coincided with a statewide 55% increase in MMR vaccine doses administered during January 1-September 26, 2025, compared with the same period in 2024. Coordinating public communication and improving access to MMR vaccine can support vaccine administration across large, rural areas and contribute to a measles outbreak response.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"52 1","pages":"111-115"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.","authors":"Sophie Zhu,Joshua Quint,Tomás M León,Nancy J Li,Shantel Muldrew,Charsey Porse,Brendan Flannery,Sascha Ellington,Erin L Murray,Darpun Sachdev,Kalyani McCullough,Robert Schechter","doi":"10.15585/mmwr.mm7509a3","DOIUrl":"https://doi.org/10.15585/mmwr.mm7509a3","url":null,"abstract":"Interim estimates of state-level influenza vaccine effectiveness (VE) can help guide timely local public health actions for prevention and treatment of influenza. Linked influenza vaccination and public health influenza surveillance data from California allowed estimation of interim influenza VE by comparing the odds of seasonal influenza vaccination among persons who received positive and negative influenza test results reported to the California Department of Public Health (CDPH) using a case-control study design. During October 1, 2025-January 31, 2026, a total of 952,765 influenza laboratory test results were reported to CDPH. These data were analyzed, including results for 86,369 (9%) persons with receipt of a positive influenza test result (case-patients) and 866,396 (91%) with receipt of a negative test result (control patients). Overall, 22% of case-patients and 27% of control patients were vaccinated against influenza. Interim VE against any influenza was 33% for all age groups, 39% for children and adolescents aged 6 months-17 years, and 22% for adults aged ≥65 years; VE was 32% against a positive influenza A test result, and 47% against a positive influenza B test result. These results suggest that influenza vaccination was associated with reduced odds for laboratory-confirmed influenza among children and adults. CDPH recommends annual influenza vaccination for all persons aged ≥6 months to reduce the risk for influenza and influenza-associated adverse health outcomes.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"15 1","pages":"124-128"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Notes from the Field: Exposures to Chemical Munitions During Commercial Fishing Operations - New Jersey, 2016-2023.","authors":"Ryan Snead,Marija Borjan,Virginia Wheatley,Katharine McGreevy,Danielle Mills","doi":"10.15585/mmwr.mm7508a3","DOIUrl":"https://doi.org/10.15585/mmwr.mm7508a3","url":null,"abstract":"","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"50 1","pages":"108-109"},"PeriodicalIF":0.0,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147359307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}